US Stock MarketDetailed Quotes
BLRX BioLine Rx
- 0.735
- +0.015+2.13%
Close Aug 23 16:00 ET
- 0.740
- +0.005+0.64%
Post 20:02 ET
58.78MMarket Cap-1623P/E (TTM)
0.759High0.701Low179.73KVolume0.701Open0.720Pre Close132.11KTurnover0.25%Turnover RatioLossP/E (Static)79.94MShares2.53052wk High4.20P/B53.55MFloat Cap0.51052wk Low--Dividend TTM72.83MShs Float103.050Historical High--Div YieldTTM8.00%Amplitude0.510Historical Low0.735Avg Price1Lot Size
BioLine Rx Stock Forum
Sign in to post a comment
There are many features available and sometimes I use interpretation of indicator to have a quick decision filter to decide if should further look at the potential investment opportunity!
4
1
$BioLine Rx (BLRX.US)$ Benzinga· 1 min ago
BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease
BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease
5
4
.$BioLine Rx (BLRX.US)$ BioLineRx To Present Poster On Economic Model Data For APHEXDA Today At ISPOR 2024
$BioLine Rx (BLRX.US)$ BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock
$BioLine Rx (BLRX.US)$ BioLineRx Announces Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production, New Patent, When Issued, Will Be Valid Until December 2041
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target: A Deep Dive into the Potential of $BLRX.
BioLine Rx (NASDAQ: $BLRX), an Israeli biopharmaceutical development company, recently received a reiterated buy rating from the renowned investment bank, HC Wainwright & Co. The financial institution has maintained a price target of $21 for BioLine Rx, indicating a positive outlook for the company's futur...
BioLine Rx (NASDAQ: $BLRX), an Israeli biopharmaceutical development company, recently received a reiterated buy rating from the renowned investment bank, HC Wainwright & Co. The financial institution has maintained a price target of $21 for BioLine Rx, indicating a positive outlook for the company's futur...
2
$BioLine Rx (BLRX.US)$ just let it run already. this is silly. youre picking up cents and it wants to move dollars 🤦🏻♂️
$BioLine Rx (BLRX.US)$ BioLineRx Entered Exclusive License Agreement To Motixafortide In Asia, Advisored By M.S.Q. Ventures; Provides $15M Upfront And Equity Investment Of $14.6M, Up To $50M In Development And Regulatory Milestones, Up To $200M In Commercial Milestones
Benzinga· 3 mins ago![]()
Benzinga· 3 mins ago
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Mooers Lab : Great screenshot!![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Add a quick analysis (30+ words) to join the 30,000 point pool! More entries (up to 10) = more points! Bonus: Share P/L for an extra 200 points!![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
For full details, check "Rewards for sharing" athttps://www.moomoo.com/community/feed/112812180045830